Publication | Closed Access

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

Open-label Phase 3MedicineMelanomaImmune Checkpoint InhibitorDermatologyPembrolizumab Versus IpilimumabImmunotherapyOncologyRadiation OncologyAdvanced MelanomaCancer Treatment